Africa CDC and Aspen Pharmacare are in advanced discussions to establish a long-term vaccine supply partnership, aimed at enhancing Africa’s vaccine manufacturing capacity and reducing reliance on imports. This move is expected to have a significant impact on the continent’s healthcare sector, with the potential to increase access to life-saving vaccines for millions of people.
Vaccine Manufacturing in Africa
The partnership between Africa CDC and Aspen Pharmacare is a major step towards achieving vaccine self-sufficiency in Africa. According to the World Health Organization, Africa imports about 99% of its vaccines, making it vulnerable to supply chain disruptions. By investing in local vaccine manufacturing, Africa can reduce its reliance on imports and improve its ability to respond to health crises.
The partnership will also involve the transfer of technology and expertise from Aspen Pharmacare to African vaccine manufacturers, which will help to build local capacity and expertise. This will enable African countries to develop and manufacture their own vaccines, reducing their dependence on foreign supplies.
Benefits of the Partnership
The partnership between Africa CDC and Aspen Pharmacare is expected to have numerous benefits, including:
- Increased access to life-saving vaccines for millions of people in Africa
- Improved vaccine manufacturing capacity in Africa, reducing reliance on imports
- Transfer of technology and expertise to African vaccine manufacturers
- Creation of jobs and economic opportunities in the healthcare sector
The partnership is also expected to have a positive impact on South Africa, where Aspen Pharmacare is based. The company is one of the largest pharmaceutical manufacturers in South Africa, and the partnership will help to boost the country’s vaccine manufacturing capacity.
As noted by the Africa Centres for Disease Control and Prevention, the partnership is a major step towards achieving the African Union’s goal of vaccine self-sufficiency by 2040. The goal is to have at least 60% of the vaccines used in Africa manufactured on the continent by 2040.
